Advertisement

Annals of Hematology

, Volume 97, Issue 9, pp 1717–1726 | Cite as

Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria

  • C. Cattaneo
  • R. Di Blasi
  • C. Skert
  • A. Candoni
  • B. Martino
  • N. Di Renzo
  • M. Delia
  • S. Ballanti
  • F. Marchesi
  • V. Mancini
  • E. Orciuolo
  • S. Cesaro
  • L. Prezioso
  • R. Fanci
  • G. Nadali
  • A. Chierichini
  • L. Facchini
  • M. Picardi
  • M. Malagola
  • V. Orlando
  • E. M. Trecarichi
  • M. Tumbarello
  • F. Aversa
  • G. Rossi
  • L. Pagano
  • on behalf of SEIFEM Group
Original Article
  • 133 Downloads

Abstract

Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A multicentric prospective observational study was planned in 18 haematological institutions during a 6-month period. All patients showing MDR rectal colonization as well as occurrence of BSI at admission were recorded. One-hundred forty-four patients with MDR colonization were observed (6.5% of 2226 admissions). Extended spectrum beta-lactamase (ESBL)-producing (ESBL-P) enterobacteria were observed in 64/144 patients, carbapenem-resistant (CR) Gram-negative bacteria in 85/144 and vancomycin-resistant enterococci (VREs) in 9/144. Overall, 37 MDR-colonized patients (25.7%) developed at least one BSI; 23 of them (62.2%, 16% of the whole series) developed BSI by the same pathogen (MDRrel BSI), with a rate of 15.6% (10/64) for ESBL-P enterobacteria, 14.1% (12/85) for CR Gram-negative bacteria and 11.1% (1/9) for VRE. In 20/23 cases, MDRrel BSI occurred during neutropenia. After a median follow-up of 80 days, 18 patients died (12.5%). The 3-month overall survival was significantly lower for patients colonized with CR Gram-negative bacteria (83.6%) and VRE (77.8%) in comparison with those colonized with ESBL-P enterobacteria (96.8%). CR-rel BSI and the presence of a urinary catheter were independent predictors of mortality. MDR rectal colonization occurs in 6.5% of haematological inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability of unfavourable outcomes in CR-rel BSIs. Tailored empiric antibiotic treatment should be decided on the basis of colonization.

Keywords

Haematologic patients Multidrug-resistant bacteria Colonization Bloodstream infections 

Notes

Acknowledgments

On behalf of SEIFEM Group, Angela Passi, Doriana Gramegna (Haematology, Spedali Civili, Brescia, Italy); Domenico Russo (Chair of Haematology, Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy); Davide Lazzarotto (Division of Haematology and Stem Cell Transplantation, University Hospital of Udine, Udine, Italy); Domenico Rotilio (Haematology Unit, Bianchi-Melacrino-Morelli Hospital, Reggio Calabria, Italy); Maria Rosaria De Paolis, UOC di Ematologia e Trapianto di Cellule Staminali“, PO “Vito Fazzi” Lecce); Edoardo Simonetti, Maria Alessandra Innocente (Institute of Haematology and Stem Cell transplantation, Ospedale Santa Maria della Misericordia, University of Perugia, Italy); Antonio Spadea (Haematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Rome, Italy); Francesco Mazziotta (Haematology Unit, Azienda Ospedaliero-Universitaria Pisana, Ospedale Santa Chiara, Pisa, Italy); Anna Pegoraro (Pediatric Haematology Oncology), Giuliana Lo Cascio (Microbiology and Virology) (Azienda Ospedaliera Universitaria integrata, Verona, Italy); Angelica Spolzino (Haematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy); Gloria Turri (Section of Haematology, Department of Clinical and Experimental Medicine, University of Verona, Italy); Barbara Veggia (UOC Ematologia Azienda Ospedaliera S. Giovanni Addolorata, Rome, Italy).

Compliance with ethical standards

The study was approved by the ethics committee of each of the participating institutions, and informed consent was obtained from all patients for being included in the study. The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rice LB (2008) Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197(8):1079–1081.  https://doi.org/10.1086/533452 CrossRefPubMedGoogle Scholar
  2. 2.
    Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A (2011) Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17(12):1798–1803.  https://doi.org/10.1111/j.1469-0691.2011.03514 CrossRefPubMedGoogle Scholar
  3. 3.
    Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55(7):943–950.  https://doi.org/10.1093/cid/cis588 CrossRefPubMedGoogle Scholar
  4. 4.
    Girmenia C, Viscoli C, Piciocchi A, Cudillo L, Botti S, Errico A, Sarmati L, Ciceri F, Locatelli F, Giannella M, Bassetti M, Tascini C, Lombardini L, Majolino I, Farina C, Luzzaro F, Rossolini GM, Rambaldi A (2015) Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica 100(9):e373–e376.  https://doi.org/10.3324/haematol.2015 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J (2011) Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66(3):657–663.  https://doi.org/10.1093/jac/dkq494 CrossRefPubMedGoogle Scholar
  6. 6.
    Rodríguez-Baño J, Picón E, Hernández JR, Cisneros JM, Peña C, Almela M, Almirante B, Grill F, Colomina J, Molinos S, Oliver A, Fernández-Mazarrasa C, Navarro G, Coloma A, López-Cerero L, Pascual A (2010) Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin Microbiol 48(5):1726–1731.  https://doi.org/10.1128/JCM.02353-09 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, Scimè R, Lombardini L, Viscoli C, Rambaldi A (2015) Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 50(2):282–288.  https://doi.org/10.1038/bmt.2014.231 CrossRefPubMedGoogle Scholar
  8. 8.
    Pagano L, Caira M, Trecarichi EM, Spanu T, Di Blasi R, Sica S, Sanguinetti M, Tumbarello M (2014) Carbapenemase-producing Klebsiella pneumoniae and hematologic malignancies. Emerg Infect Dis 20(7):1235–1236.  https://doi.org/10.3201/eid2007.130094 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Trecarichi EM, Pagano L, Candoni A, Pastore D, Cattaneo C, Fanci R, Nosari A, Caira M, Spadea A, Busca A, Vianelli N, Tumbarello M (2015) Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: an Italian multicentre prospective survey. Clin Microbiol Infect 21(4):337–343.  https://doi.org/10.1016/j.cmi.2014.11.022 CrossRefPubMedGoogle Scholar
  10. 10.
    Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13(5):615–621CrossRefPubMedGoogle Scholar
  11. 11.
    Gedik H, Yıldırmak T, Simşek F, Kantürk A, Arıca D, Aydın D, Yokuş O, Demirel N, Arabacı C (2014) Vancomycin-resistant enterococci colonization and bacteremia in patients with hematological malignancies. J Infect Dev Ctries 8(9):1113–1118.  https://doi.org/10.4314/ahs.v14i4.18 CrossRefPubMedGoogle Scholar
  12. 12.
    Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H (2014) A multicenter cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. J Antimicrob Chemother 69(12):3387–3392.  https://doi.org/10.1093/jac/dku305 CrossRefPubMedGoogle Scholar
  13. 13.
  14. 14.
    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281.  https://doi.org/10.1111/j.1469-0691.2011.03570.x CrossRefPubMedGoogle Scholar
  15. 15.
    Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40(6):613–619.  https://doi.org/10.1007/s15010-012-0269-y CrossRefPubMedGoogle Scholar
  16. 16.
    Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, Noskin GA, Zembower T (2007) Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 45(7):846–852CrossRefPubMedGoogle Scholar
  17. 17.
    Alevizakos M, Karanika S, Detsis M, Mylonakis E (2016) Colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk for infection among patients with solid or haematological malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents 48(6):647–654.  https://doi.org/10.1016/j.ijantimicag.2016.08.021 CrossRefPubMedGoogle Scholar
  18. 18.
    Zaas AK, Song X, Tucker P, Perl TM (2002) Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis 35(10):1139–1146CrossRefPubMedGoogle Scholar
  19. 19.
    Cornejo-Juárez P, Suárez-Cuenca JA, Volkow-Fernández P, Silva-Sánchez J, Barrios-Camacho H, Nájera-León E, Velázquez-Acosta C, Vilar-Compte D (2016) Fecal ESBL Escherichia coli carriage as a risk factor for bacteremia in patients with hematological malignancies. Support Care Cancer 24(1):253–259CrossRefPubMedGoogle Scholar
  20. 20.
    Cattaneo C, Zappasodi P, Mancini V, Annaloro C, Pavesi F, Skert C, Ferrario A, Todisco E, Saccà V, Verga L, Passi A, Da Vià M, Ferrari S, Mometto G, Petullà M, Nosari A, Rossi G (2016) Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel). Ann Hematol 95(12):1955–1963CrossRefPubMedGoogle Scholar
  21. 21.
    Trecarichi EM, Pagano L, Martino B, Candoni A, Di Blasi R, Nadali G, Fianchi L, Delia M, Sica S, Perriello V, Busca A, Aversa F, Fanci R, Melillo L, Lessi F, Del Principe MI, Cattaneo C, Tumbarello M (2016) Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol 91(11):1076–1081.  https://doi.org/10.1002/ajh.24489 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • C. Cattaneo
    • 1
  • R. Di Blasi
    • 2
  • C. Skert
    • 3
  • A. Candoni
    • 4
  • B. Martino
    • 5
  • N. Di Renzo
    • 6
  • M. Delia
    • 7
  • S. Ballanti
    • 8
  • F. Marchesi
    • 9
  • V. Mancini
    • 10
  • E. Orciuolo
    • 11
  • S. Cesaro
    • 12
  • L. Prezioso
    • 13
  • R. Fanci
    • 14
  • G. Nadali
    • 15
  • A. Chierichini
    • 16
  • L. Facchini
    • 17
  • M. Picardi
    • 18
  • M. Malagola
    • 3
  • V. Orlando
    • 1
  • E. M. Trecarichi
    • 19
  • M. Tumbarello
    • 19
  • F. Aversa
    • 13
  • G. Rossi
    • 1
  • L. Pagano
    • 2
  • on behalf of SEIFEM Group
  1. 1.HaematologySpedali CiviliBresciaItaly
  2. 2.Institute of HaematologyUniversità Cattolica S. CuoreRomeItaly
  3. 3.Chair of Haematology, Unit of Blood Diseases and Stem Cell TransplantationUniversity of BresciaBresciaItaly
  4. 4.Division of Haematology and Stem Cell TransplantationUniversity Hospital of UdineUdineItaly
  5. 5.Haematology UnitBianchi-Melacrino-Morelli HospitalReggio CalabriaItaly
  6. 6.UOC di Ematologia e Trapianto di Cellule Staminali”LecceItaly
  7. 7.Haematology DivisionUniversity of BariBariItaly
  8. 8.Institute of Haematology and Stem Cell transplantation, Ospedale Santa Maria della MisericordiaUniversity of PerugiaPerugiaItaly
  9. 9.Haematology and Stem Cell Transplantation UnitRegina Elena National Cancer InstituteRomeItaly
  10. 10.Department of Haematology and OncologyA.O. Ospedale Niguarda Cà GrandaMilanItaly
  11. 11.Haematology UnitAzienda Ospedaliero-Universitaria Pisana, Ospedale Santa ChiaraPisaItaly
  12. 12.Pediatric Haematology OncologyAzienda Ospedaliera Universitaria IntegrataVeronaItaly
  13. 13.Haematology and BMT UnitAzienda Ospedaliero-Universitaria di ParmaParmaItaly
  14. 14.Haematology UnitCareggi Hospital and University of FlorenceFlorenceItaly
  15. 15.Section of Hematology, Department of Clinical and Experimental MedicineUniversity of VeronaVeronaItaly
  16. 16.UOC Ematologia Azienda Ospedaliera S. Giovanni AddolorataRomeItaly
  17. 17.Haematology UnitAO S. Maria Nuova, IRCCSReggio EmiliaItaly
  18. 18.Dipartimento di Scienze Biomediche AvanzateUniversità Federico II NapoliNaplesItaly
  19. 19.Institute of Infectious DiseaseUniversità Cattolica S. CuoreRomeItaly

Personalised recommendations